To assess the HER2+ tumor targeting efficiency at the cellular level, cancer cells (4T1 and SK-OV-3 overexpressing HER2) and normal cells (J774A.1 macrophages) were utilized, as illustrated in Fig. 3A, D, and 3G. The gene discussed is ERBB2; the disease is neoplasm.